Yoon Hyeon Jeong, Kim Jonghwa, Yang Jee Myung, Wei Edward T, Kim Seong Jin, Yoon Kyung Chul
Department of Ophthalmology, Chonnam National University Medical School and Hospital, 42 Jebong-ro, Dong-gu, Gwangju 61469, Korea.
Department of Ophthalmology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-Ro 43 Gil, Songpa-gu, Seoul 05505, Korea.
J Clin Med. 2021 Jan 12;10(2):250. doi: 10.3390/jcm10020250.
Activation of TRPM8, a cold-sensing receptor located on the cornea and eyelid, has the potential to relieve the neuropathic ocular pain (NOP) in dry eye (DE) by inhibiting other aberrant nociceptive inputs. We aimed to investigate the effect of a topical TRPM8 agonist, cryosim-3 (C3), on relieving DE-associated NOP.
We conducted a prospective pilot study of 15 patients with DE-associated NOP. These patients applied topical C3 to their eyelid, 4 times/day for 1 month. The patients underwent clinical examinations. They also completed the Ocular Pain Assessment Survey (OPAS), which is a validated questionnaire for NOP, at baseline, 1 week, and 1 month after treatment.
At 1 week, the OPAS scores of eye pain intensity, quality of life (driving/watching TV, general activity, sleep, and enjoying life/relations with other people), and associated factors (burning sensation, light sensitivity, and tearing) improved. The total OPAS scores of eye pain intensity, quality of life, and associated factors remained improved at 1 month. The Schirmer test scores also improved at 1 month.
TRPM8 agonist (C3) could be a novel agent for treating patients with DE-associated NOP who are unresponsive to conventional treatments.
TRPM8是一种位于角膜和眼睑的冷敏受体，激活该受体有可能通过抑制其他异常伤害性输入来缓解干眼（DE）相关的神经性眼痛（NOP）。我们旨在研究局部应用TRPM8激动剂cryosim-3（C3）对缓解DE相关NOP的效果。
我们对15例DE相关NOP患者进行了一项前瞻性试点研究。这些患者每天4次在眼睑局部应用C3，持续1个月。患者接受了临床检查。他们还在治疗前、治疗1周和1个月时完成了眼痛评估调查（OPAS），这是一份经过验证的NOP问卷。
在1周时，眼痛强度、生活质量（驾驶/看电视、一般活动、睡眠以及享受生活/与他人的关系）和相关因素（烧灼感、光敏感和流泪）的OPAS评分有所改善。在1个月时，眼痛强度、生活质量和相关因素方面的OPAS总分仍保持改善。泪液分泌试验评分在1个月时也有所改善。
TRPM8激动剂（C3）可能是一种治疗对传统治疗无反应的DE相关NOP患者的新型药物。
